Table 2 Efficacy end-point analysis (efficacy set population) in patients receiving a single dose of NEPA and dexamethasone
Overall period (days 1 to 5) | Acute period (day 1) | Delayed period (days 2 to 5) | ||||
|---|---|---|---|---|---|---|
N (%) | 90% CI | N (%) | 90% CI | N (%) | 90% CI | |
Cycle 1 (N = 139) | ||||||
CR | 98 (70.5) a | 64.1; 76.9b | 119 (85.6) | 80.7; 90.5 | 101 (72.7) | 66.4; 78.9 |
NSN | 80 (57.6) | 50.7; 64.5 | 113 (81.3) | 75.9; 86.7 | 85 (61.2) | 54.4; 68.0 |
Cycle 2 (N = 139) | ||||||
CR | 98 (70.5) | 64.1; 76.9 | 118 (84.9) | 79.9; 89.9 | 102 (73.4) | 67.2; 79.6 |
NSN | 79 (56.8) | 49.9; 63.7 | 101 (72.7) | 66.4; 78.9 | 81 (58.3) | 51.4; 65.2 |
Cycle 3 (N = 138) | ||||||
CR | 100 (72.5) | 66.2; 78.7 | 115 (83.3) | 78.1; 88.6 | 104 (75.4) | 69.3; 81.4 |
NSN | 85 (61.6) | 54.8; 68.4 | 102 (73.9) | 67.8; 80.1 | 88 (63.8) | 57.0; 70.5 |
Cycle 4 (N = 136) | ||||||
CR | 96 (70.6) | 64.2; 77.0 | 106 (77.9) | 72.1; 83.8 | 100 (73.5) | 67.3; 79.8 |
NSN | 82 (60.3) | 53.4; 67.2 | 95 (69.9) | 63.4; 76.3 | 87 (64.0) | 57.2; 70.7 |